Persistent competition in key therapeutic areas, headwinds from lower COVID-19 product revenues and rising threats on the US drug pricing front are putting more pressure on new brands to deliver future growth for big pharmaceutical companies.
The industry’s first quarter sales and earnings reporting season set the stage for a year that is poised to deliver...